Selected Publications

Hergenroeder, G. Shenoy, A. : Cystic Fibrosis. In: Ferri’s Clinical Advisor 2026. Elsevier; In Press. 2026.

Georgene E. Hergenroeder, Kevin J. Psoter, Cynthia D. Brown, Josh Ostrenga, Christine Ford, Lisa Bendy, Bradley H. Rosen, Nell Meosky Luo, Connie Zhang, Kathryn A. Sabadosa, Clement L. Ren: Baseline Characteristics and Self-Reported Use of Chronic Daily Therapies of the Home Reported Outcomes With CFTR Modulator Therapy (HERO-2) Cohort. Pediatric Pulmonology 60(7), July 2025 Notes: https://doi.org/10.1002/ppul.71190.

Georgene E Hergenroeder, Jonathan V Todd, Josh S. Ostrenga, Christopher H Goss, Raksha Jain, Wayne Morgan, Gregory S. Sawicki, Michael S Schechter, Elizabeth A Cromwell, Clement L Ren: Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. Journal of Cystic Fibrosis 24(1): 135-141, January 2025 Notes: DOI: 10.1016/j.jcf.2024.10.006

Rosen BH, Psoter KJ, Sabadosa KA, Hergenroeder GE, Bendy LL, Luo NM, Zhang C, Ren CL, Brown CD: Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis: The Home Reported Outcomes in Cystic Fibrosis 2 (HERO-2) Study Design. CHEST Pulmonary December 2024 Notes: https://doi.org/10.1016/j.chpulm.2024.100080.

Georgene E. Hergenroeder, Kevin J. Psoter, Cynthia D. Brown, Kathryn A. Sabadosa, Bradley H. Rosen, Lisa L. Bendy, Connie Zhang, Clement L. Ren: Outcomes of Diverse Recruitment Strategies in the Home Reported Outcomes with CFTR Modulator Therapy (HERO-2) Study. Journal of Cystic Fibrosis 23: 401-S402, September 2024 Notes: 10.1016/S1569-1993(24)01549-2.

Hergenroeder, G. Todd, J. Ostrenga, J. Goss, C. Jain, Raksha Morgan, W. Sawicki, Gregory Schechter, M. Cromwell, E. Ren, Clement L.: Real-world impact of elexacaftor/tezacaftor/ivacaftor on pulmonary and nutritional outcomes in people with cystic fibrosis. Journal of Cystic Fibrosis 23: S391-S392, September 2024 Notes: DOI: 10.1016/S1569-1993(24)01536-4.

G. Hergenroeder, JT, C. Goss, R. Jain, W. Morgan, G. Sawicki, M. Schechter, C. Ren. : Black and Hispanic people with cystic fibrosis (PwCF) and PwCF with high lung function are less likely to be prescribed elexacaftor-tezacaftor-ivacaftor despite having an eligible genotype. J Cystic Fibros 22: S205-206, October 2023 Notes: DOI:10.1016/S1569-1993(23)01328-0.

G. Hergenroeder, K. Psoter, C. Brown, K. Sabadosa, L. Bendy, B. Rosen, N. Luo, C. Zhang, C. Ren: Clinical features associated with changes in chronic daily therapies in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor: Results from the Home Reported Outcomes 2 Study Journal of Cystic Fibrosis 22: S325, October 2023 Notes: DOI: 10.1016/S1569-1993(23)01532-1.

Hergenroeder, G.E., Faino, A.V., Cogen, J.D., Genatossio, A., McNamara, S., Pascual, M., & Hernandez, R.E: Seroprevalence and clinical characteristics of SARSCoV‐2 infection in children with cystic fibrosis. Pediatric Pulmonology September 2023 Notes: https://doi.org/10.1002/ppul.26528.

Hergenroeder, G.E., Faino, A., Bridges, G., Bartlett, L.E., Cogen, J.D., Green, N., McNamara, S., Nichols, D.P., & Ramos, K.J. : The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis. Journal of Cystic Fibrosis August 2023 Notes: https://doi.org/10.1016/j.jcf.2023.08.002.